Two New Insulin Products Join the Market
Lyumjev (insulin lispro-aabc) is the first insulin approved as a biologic and is the second ultra-rapid-acting mealtime insulin. It starts working about 10 minutes faster than other lispro products like Admelog and Humalog due to additives that speed absorption. Lyumjev’s A1c reduction and hypoglycemia risk are similar to Humalog.
Semglee (insulin glargine) is the second “follow-on” brand to Lantus U-100. Semglee carries the exact same indications and amino acid sequence as Lantus. It is expected that Semglee will be less expensive than other forms of insulin glargine.
These products are not generic and typically cannot be automatically substituted by the pharmacy. Continue to prescribe preferred insulin products as specified by the health plans.